Peptide Reference
5-Amino-1MQ
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT (nicotinamide N-methyltransferase) that increases NAD+ levels and metabolic rate. Non-peptide compound taken orally.
Status
research
Category
weight loss
Typical cost
$60-120/month
Mechanism
Inhibits NNMT enzyme, which is elevated in obesity and diabetes. Reduces methylation of nicotinamide, increasing NAD+ levels and activating sirtuins. Enhances metabolic rate and fat oxidation.
Potential benefits
- Increased metabolic rate
- Enhanced fat oxidation
- Improved body composition
- Higher NAD+ levels
- Better insulin sensitivity
- NNMT inhibition
- Elevated NAD+
- Fat metabolism
- Lean mass preservation
- Metabolic efficiency
Reported side effects
- Unknown long-term safety
- Potential liver effects
- Nausea
- Headache
- Very limited data
- Unknown long-term effects
- Injection site reactions
Common dosing references
oral
50-150mg · Daily
8-12 weeks
subcutaneous
2.5-5mg · 1-2x daily
4-8 weeks
Research notes
NNMT inhibition in obesity models
2018
Demonstrated reduced fat mass and improved glucose tolerance in animal models
5-Amino-1MQ NNMT inhibition
2019
Demonstrated NNMT inhibition and metabolic benefits in preclinical models
Regulatory and sourcing notes
Research chemical only. Not FDA-approved. No human clinical trials completed.
Research chemical with limited human data. Use caution. Not a peptide but often grouped with metabolic agents.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.